Welcome to our dedicated page for Senestech SEC filings (Ticker: SNES), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SenesTech, Inc. filings document the public-company records of a Nasdaq-listed developer of fertility-control products for rodent and animal pest management. Recent Form 8-K reports cover operating results, commercial updates tied to e-commerce and Evolve products, and material governance events involving executive appointments, departures, employment terms, and compensation arrangements.
SenesTech proxy materials describe annual meeting matters, board and executive compensation disclosures, shareholder voting items, and governance information. The filings also identify the company’s registered common stock, par value, trading symbol SNES, and Nasdaq listing, providing formal disclosure around capital structure and corporate administration.
Glenbrook Capital Management, as investment manager for a client account, reported open-market purchases of SenesTech common stock, increasing that account’s indirect holdings. The account bought 15,000 shares on May 14, 2026 at $1.7241 per share, 7,120 shares on May 15, 2026 at $1.6498, and 10,000 shares on May 18, 2026 at $1.5878. After these transactions, the account held 925,755 SenesTech shares indirectly managed by Glenbrook, which disclaims beneficial ownership beyond any pecuniary interest.
SenesTech, Inc. director and CEO Michael Edell bought additional company stock in two open-market transactions. He purchased 2,000 shares of Common Stock on May 14, 2026 at $1.6988 per share and 1,000 shares on May 15, 2026 at $1.615 per share, all held directly.
After these buys, Edell directly owns 3,000 shares of SenesTech common stock. A footnote explains that one transaction price reflects a weighted average for purchases between $1.69 and $1.705 per share.
SenesTech, Inc. reported first-quarter 2026 results with revenue of $493,000, up slightly from $485,000 a year earlier, as its Evolve fertility-control products grew to 85% of sales while ContraPest declined. Gross profit was $338,000, for a margin of 68.6%, reflecting improved production efficiency and pricing.
The company posted a net loss of $2.1 million, compared with $1.7 million in the prior-year quarter, driven mainly by higher selling, general and administrative expenses, including legal costs tied to a settled litigation matter and severance and search expenses related to leadership changes. Operating cash use was $1.9 million.
Cash, cash equivalents and short-term investments totaled $6.8 million as of March 31, 2026, versus $8.6 million at year-end 2025. Management expects existing cash and anticipated revenue to fund operations into the third quarter of 2027. During the quarter, SenesTech raised $173,000 net via its at-the-market equity facility and ended with total assets of $11.1 million and stockholders’ equity of $7.7 million.
SenesTech reported modest Q1 2026 growth as it shifts to a recurring, e-commerce driven model. Revenue rose 2% to $493,000, while gross profit increased to $338,000 and gross margin reached a company record 68.6% as higher-margin channels expanded.
Direct-to-consumer revenue grew 42% to $194,000 and subscription revenue rose 44% to $56,000, partly offsetting a deliberate reduction in third-party e-commerce sales during the transition to in-house Amazon management. B2B revenue increased 57% to $298,000 across distributor, municipal, and professional channels.
Net loss widened to $2.1 million, including $443,000 of severance and one-time legal costs, and adjusted EBITDA loss was $1.6 million. SenesTech ended the quarter with $6.8 million in cash and equivalents and highlighted strong April 2026 e-commerce momentum, with online sales up 163% year over year to $146,000. The company also emphasized its new CEO, e-commerce site redesign, packaging refresh, and growing municipal and international activity.
SenesTech, Inc. appointed Michael Edell as its new President and Chief Executive Officer effective May 6, 2026, succeeding Joel L. Fruendt, and also named him to the Board as a Class III director with a term running to the 2028 annual meeting. Edell previously served as Interim Chief Operating Officer overseeing day-to-day operations and commercial strategy. Under his employment agreement, he will receive a $360,000 annual base salary and be eligible for an annual bonus targeted at 60% of base salary, pro rated for 2026 from April 1. He was also granted an option to purchase 5.0% of SenesTech’s outstanding common shares, vesting over three years in quarterly installments and exercisable only if stockholders approve an increase to the 2018 Equity Incentive Plan. If terminated without cause or he resigns for good reason, he may receive salary and healthcare continuation for up to 12 months, full vesting of the option, and a pro rated bonus for the year of termination. Jamie Bechtel’s role as Interim Executive Chair concluded in connection with Edell’s appointment.
SenesTech, Inc. appointed Michael Edell as its new President and Chief Executive Officer effective May 6, 2026, succeeding Joel L. Fruendt, and also named him to the Board as a Class III director with a term running to the 2028 annual meeting. Edell previously served as Interim Chief Operating Officer overseeing day-to-day operations and commercial strategy. Under his employment agreement, he will receive a $360,000 annual base salary and be eligible for an annual bonus targeted at 60% of base salary, pro rated for 2026 from April 1. He was also granted an option to purchase 5.0% of SenesTech’s outstanding common shares, vesting over three years in quarterly installments and exercisable only if stockholders approve an increase to the 2018 Equity Incentive Plan. If terminated without cause or he resigns for good reason, he may receive salary and healthcare continuation for up to 12 months, full vesting of the option, and a pro rated bonus for the year of termination. Jamie Bechtel’s role as Interim Executive Chair concluded in connection with Edell’s appointment.
Glenbrook Capital Management-related entities acquired additional SenesTech, Inc. shares in the open market. On the reported date, PFS Trust, the Glenbrook Capital Management Inc. Employee Profit-Sharing Plan, and various managed funds together purchased 3,000 shares of SenesTech common stock at $1.469 per share, bringing their indirect holdings reported in this filing to 893,635 shares. Glenbrook Capital Management, as investment manager, disclaims beneficial ownership beyond any pecuniary interest.
SenesTech, Inc. is asking stockholders to vote at its June 9, 2026 annual meeting on board elections, executive pay and key governance items. Two Class I directors, Jake S. Leach and Joshua M. Moss, are nominated for new three-year terms. Stockholders will cast a non-binding say-on-pay vote on 2025 compensation for the CEO and other named executives, and vote on amending the 2018 Equity Incentive Plan to add 1,700,000 shares of common stock for future equity awards. They will also vote on ratifying M&K CPAS, PLLC as independent auditor for 2026. Holders of 5,265,744 shares outstanding as of April 20, 2026 may vote by internet, telephone, mail or in person, with detailed rules for quorums, broker non-votes and proposal approval thresholds.
SenesTech, Inc. disclosure: Glenbrook Capital Management reports beneficial ownership of 890,635 shares of Common Stock, representing 16.8% of the class based on 5,303,426 shares outstanding as of March 11, 2026. The filing states these shares are held by affiliated vehicles, including PFS Trust, and that shared voting and dispositive power is reported.
SenesTech, Inc. reported that entities managed by Glenbrook Capital Management made open-market purchases of a total of 171,034 shares of Common Stock on March 13, 16 and 17, 2026, at prices between $1.79 and $1.95 per share.
After these transactions, the Glenbrook-managed accounts indirectly held 890,635 SenesTech shares. A footnote explains that this filing also corrects a prior understatement of beneficially owned shares in an earlier Form 4.
SenesTech, Inc. files its annual report describing a rodent fertility-control business built around ContraPest liquid bait and Evolve Rat and Evolve Mouse soft baits. These products target reproduction rather than killing, are positioned within integrated pest management programs, and benefit from minimum-risk or EPA registrations.
The company highlights growing regulatory scrutiny of anticoagulant rodenticides and positions its non-lethal, environmentally focused products as alternatives. It reports net losses of $6.4 million in 2025 and $6.2 million in 2024, with an accumulated deficit of $142.5 million, and warns it will need additional capital and broader market adoption to reach profitability.